Compare American Water Works Company Inc (AWK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Recursion Pharmaceuticals Inc — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: American Water Works Company Inc is far larger — about 14.4× Recursion Pharmaceuticals Inc's market cap, and American Water Works Company Inc pays a 2.72% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AWK | RXRX | |
|---|---|---|
Market Cap | $25.69B | $1.78B |
Sector | Utilities | Health |
52-Week High | $147.00 | $6.79 |
52-Week Low | $121.13 | $2.84 |
Enterprise Value | $41.25B | $1.19B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Water Works (AWK) trades at $131.53, up 0.64% with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth from $3.8B in 2022 to $5.14B in 2025, maintaining net margins above 21%. Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while the company continues infrastructure investments and community initiatives.
AWK presents a stable utility investment with moderate upside to the $137 consensus target. Key risks include regulatory approvals for rate increases and high capital expenditures. Analyst sentiment is balanced with 47% buy ratings, though recent earnings misses warrant caution ahead of Q2 2026 results on July 29, 2026.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
